Inflammation and atherosclerosis - Revisited

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 2, 2014, Pages 170-178

  Pant, Sadip ^a   Deshmukh, Abhishek ^a   Gurumurthy, Guru S ^a   Pothineni, Naga Venkata ^a   Watts, Thomas Evans ^a   Romeo, Francesco ^b   Mehta, Jawahar L ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

atherogenesis; atherosclerosis; coronary artery disease; inflammation

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS;

EID: 84894437263     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413504994     Document Type: Review

References (72)

1. Heart and Stroke Statistical Update. Dallas, TX: American Heart Association ; 1997:
2. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008 ; 54 (1). 24-38
3. Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol. 1997 ; 80 (9A). 11I - 16I
4. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994 ; 84 (7). 2068-2101
5. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood. 2008 ; 111 (11). 5271-5281
6. Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 2003 ; 24 (6). 327-334
7. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2000 ; 191 (1). 189-194
8. Smith JD, Dansky HM, Breslow JL. Genetic modifiers of atherosclerosis in mice. Ann N Y Acad Sci. 2001 ; 947: 247-252
9. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006 ; 86 (2). 515-581
10. Jy W, Mao WW, Horstman L, Tao J, Ahn YS. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis. 1995 ; 21 (3). 217-231
11. Schrijvers DM, De Meyer GR, Herman AG, Martinet W.. Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability. Cardiovasc Res. 2007 ; 73 (3). 470-480
12. Lu J, Mitra S, Wang X, Khaidakov M, Mehta JL. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid Redox Signal. 2011 ; 15 (8). 2301-2333
13. Alon R, Ley K. Cells on the run: shear-regulated integrin activation in leukocyte rolling and arrest on endothelial cells. Curr Opin Cell Biol. 2008 ; 20 (5). 525-532
14. Yang BC, Nichols WW, Lawson DL. Mehta JL. 5-Hydroxytryptamine potentiates vasoconstrictor effect of endothelin-1. Am J Physiol. 1992 ; 262 (4 pt 2). H931 - H936
15. Hulsmans M, Holvoet P. The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med. 2010 ; 14 (1-2). 70-78
16. Wong BW, Meredith A, Lin D, McManus BM. The biological role of inflammation in atherosclerosis. Can J Cardiol. 2012 ; 28 (6). 631-641
17. Hulsmans M, Van Dooren E, Holvoet P. Mitochondrial reactive oxygen species and risk of atherosclerosis. Curr Atheroscler Rep. 2012 ; 14 (3). 264-276
18. Naik E, Dixit VM. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med. 2011 ; 208 (3). 417-420
19. Marwali MR, Mehta JL. COX-2 inhibitors and cardiovascular risk. inferences based on biology and clinical studies. Thromb Haemost. 2006 ; 96 (4). 401-406
20. Mitra S, Goyal T, Mehta JL, Oxidized LDL. LOX-1 and atherosclerosis. Cardiovasc Drugs Ther. 2011 ; 25 (5). 419-429
21. Shah PK. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther. 2009 ; 23 (1). 31-40
22. Methe H, Brunner S, Wiegand D, Nabauer M, Koglin J, Edelman ER. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol. 2005 ; 45 (12). 1939-1945
23. Getz GS. Thematic review series: the immune system and atherogenesis. immune function in atherogenesis. J Lipid Res. 2005 ; 46 (1). 1-10
24. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse?. Arterioscler Thromb Vasc Biol. 2006 ; 26 (11). 2421-2432
25. Hollan I, Meroni PL, Ahearn JM, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013 ; 12 (10). 1004-1015
26. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 1998 ; 31 (7). 1460-1465
27. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol. 2000 ; 35 (6). 1535-1542
28. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med. 2000 ; 343 (16). 1139-1147
29. Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002 ; 105 (12). 1412-1415
30. Dhingra R, Gona P, Nam BH, et al. C-reactive protein, inflammatory conditions, and cardiovascular disease risk. Am J Med. 2007 ; 120 (12). 1054-1062
31. Hung J, Knuiman MW, Divitini ML, Davis T, Beilby JP. Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. Am J Cardiol. 2008 ; 101 (2). 193-198
32. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006 ; 145 (1). 35-42
33. Kennon S, Timmis AD, Whitbourn R, Knight C. C reactive protein for risk stratification in acute coronary syndromes? Verdict: unproven. Heart. 2003 ; 89 (11). 1288-1290
34. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003 ; 349 (17). 1595-1604
35. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003 ; 108 (12). 1440-1445
36. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction. a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000 ; 102 (19). 2329-2334
37. Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. Am J Cardiol. 2001 ; 87 (5). 636-639
38. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol. 2004 ; 44 (10). 1945-1956
39. Morrow DA, Rifai N, Antman EM, et al. Serum amyloid a predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 2000 ; 35 (2). 358-362
40. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S.. New markers of inflammation and endothelial cell activation: Part I. Circulation. 2003 ; 108 (16). 1917-1923
41. Cipollone F, Marini M, Fazia M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001 ; 21 (3). 327-334
42. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003 ; 107 (5). 690-695
43. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008 ; 101 (12A). 23F - 33F
44. Yang EH, McConnell JP, Lennon RJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2006 ; 26 (1). 106-111
45. Mehta JL, Li DY. Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain?. Cardiovasc Res. 1999 ; 43 (2). 291-299
46. Park JG, Ryu SY, Jung IH, et al. Evaluation of VCAM-1 antibodies as therapeutic agent for atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2013 ; 226 (2). 356-363
47. Schapira K, Lutgens E, de Fougerolles A, et al. Genetic deletion or antibody blockade of alpha1beta1 integrin induces a stable plaque phenotype in ApoE-/- mice. Arterioscler Thromb Vasc Biol. 2005 ; 25 (9). 1917-1924
48. Pepine CJ, Hirshfeld JW, Macdonald RG, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation. 1990 ; 81 (6). 1753-1761
49. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324 (7329). 71-86
50. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr. 2010 ; 30: 173-199
51. Landberg R, Naidoo N, van Dam RM. Diet and endothelial function: from individual components to dietary patterns. Curr Opin Lipidol. 2012 ; 23 (2). 147-155
52. Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 ; 371 (9626). 1761-1768
53. Hernández-Presa MA, Martín-Ventura JL, Ortega M, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002 ; 160 (1). 49-58
54. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998 ; 98 (9). 839-844
55. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 ; 352 (1). 20-28
56. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005 ; 352 (1). 29-38
57. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque stability. Circulation. 2000 ; 101 (12). 1372-1378
58. Khan Q, Mehta JL. Relevance of platelet-independent effects of aspirin to its salutary effect in atherosclerosis-related events. J Atheroscler Thromb. 2005 ; 12 (4). 185-190
59. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 ; 336 (14). 973-979
60. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002 ; 106 (6). 679-684
61. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011 ; 342: d1309
62. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT. J Thromb Haemost. 2009 ; (7 suppl 1). 332-329
63. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J. 2011 ; 162 (4). 597-605
64. Boekholdt SM, de Winter RJ, Kastelein JJ. Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?. Circulation. 2008 ; 118 (11). 1120-1122
65. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res [Internet]. 1999 ; 84 (9). 1043-1049
66. Murase T, Kume N, Korenaga R, et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res [Internet]. 1998 ; 83 (3). 328-333
67. Li D, Mehta JL. Intracellular signaling of LOX-1 in endothelial cell apoptosis. Circ Res [Internet]. 2009 ; 104 (5). 566-568
68. Ryoo S, Bhunia A, Chang F, Shoukas A, Berkowitz DE, Romer LH. OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis [Internet]. 2011 ; 214 (2). 279-287
69. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation [Internet]. 2000 ; 101 (25). 2889-2895
70. Hu C, Dandapat A, Sun L, et al. LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovasc Res [Internet]. 2008 ; 79 (2). 287-293
71. Hayashida K, Kume N, Murase T, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation. 2005 ; 112 (6). 812-818
72. Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis. 2006 ; 184 (2). 295-301